200,000+ products from a single source!
sales@angenechem.com
Home > Fluorides > 114248-23-6
114248-23-6 | Uridine, 2'-deoxy-2',2'-difluoro-
CAS No: 114248-23-6 Catalog No: AG000AWJ MDL No:MFCD00871912
Product Description
Catalog Number:
AG000AWJ
Chemical Name:
Uridine, 2'-deoxy-2',2'-difluoro-
CAS Number:
114248-23-6
Molecular Formula:
C9H10F2N2O5
Molecular Weight:
264.1829
MDL Number:
MFCD00871912
IUPAC Name:
1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
InChI:
InChI=1S/C9H10F2N2O5/c10-9(11)6(16)4(3-14)18-7(9)13-2-1-5(15)12-8(13)17/h1-2,4,6-7,14,16H,3H2,(H,12,15,17)/t4-,6-,7-/m1/s1
InChI Key:
FIRDBEQIJQERSE-QPPQHZFASA-N
SMILES:
OC[C@H]1O[C@H](C([C@@H]1O)(F)F)n1ccc(=O)[nH]c1=O
UNII:
Y30D8SIL1I
Properties
Complexity:
414
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
3
Defined Bond Stereocenter Count:
0
Exact Mass:
264.056g/mol
Formal Charge:
0
Heavy Atom Count:
18
Hydrogen Bond Acceptor Count:
7
Hydrogen Bond Donor Count:
3
Isotope Atom Count:
0
Molecular Weight:
264.185g/mol
Monoisotopic Mass:
264.056g/mol
Rotatable Bond Count:
2
Topological Polar Surface Area:
99.1A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-1.3
Literature
| Title | Journal |
|---|---|
| Localized delivery of chemotherapy to the cervix for radiosensitization. | Gynecologic oncology 20121001 |
| Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells. | Pharmaceutical research 20120701 |
| Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. | Pharmacogenomics 20120701 |
| Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine. | Expert opinion on investigational drugs 20120401 |
| [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20120101 |
| Determination of the phosphorylated metabolites of gemcitabine and of difluorodeoxyuridine by LCMSMS. | Nucleosides, nucleotides & nucleic acids 20111201 |
| A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy. | Cancer chemotherapy and pharmacology 20111101 |
| The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase. | Drug metabolism and disposition: the biological fate of chemicals 20111101 |
| Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110915 |
| Difluorodeoxyuridine plasma concentrations after low-dose gemcitabine during chemoradiation in head and neck cancer patients. | Cancer chemotherapy and pharmacology 20110701 |
| Effect of its deaminated metabolite, 2',2'-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells. | Biochemical pharmacology 20110401 |
| Combinatorial pharmacologic effects of gemcitabine and its metabolite dFdU. | ChemMedChem 20110307 |
| [Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs]. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20110201 |
| Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites. | Chemosphere 20100901 |
| Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. | Clinical pharmacokinetics 20100801 |
| Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. | Journal of controlled release : official journal of the Controlled Release Society 20100601 |
| Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. | European journal of clinical pharmacology 20100601 |
| Gemcitabine and epirubicin plasma concentration-related excretion in saliva in patients with non-small cell lung cancer. | Therapeutic drug monitoring 20100601 |
| Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer. | Urology 20091101 |
| Simultaneous quantification of 2',2'-difluorodeoxycytidine and 2',2'-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20091001 |
| Development of a sensitive and selective LC-MS/MS method for simultaneous determination of gemcitabine and 2,2-difluoro-2-deoxyuridine in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090715 |
| Mass flows of X-ray contrast media and cytostatics in hospital wastewater. | Environmental science & technology 20090701 |
| Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: development of a liquid chromatography-tandem mass spectrometry method. | Journal of chromatography. A 20090410 |
| Challenge of high polarity and low concentrations in analysis of cytostatics and metabolites in wastewater by hydrophilic interaction chromatography/tandem mass spectrometry. | Journal of chromatography. A 20090213 |
| A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites. | Cancer chemotherapy and pharmacology 20090101 |
| Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function. | Clinical pharmacokinetics 20090101 |
| Does saturable formation of gemcitabine triphosphate occur in patients? | Cancer chemotherapy and pharmacology 20081201 |
| Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. | Drug metabolism and disposition: the biological fate of chemicals 20080801 |
| New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. | Molecular cancer therapeutics 20080801 |
| Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. | Cancer chemotherapy and pharmacology 20080701 |
| A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080701 |
| Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080601 |
| Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer. | Japanese journal of clinical oncology 20080301 |
| Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. | The oncologist 20080301 |
| Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry. | Journal of mass spectrometry : JMS 20080201 |
| Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. | Cancer chemotherapy and pharmacology 20070201 |
| Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070101 |
| Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer. | Anticancer research 20070101 |
| Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20070101 |
| Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. | Journal of mass spectrometry : JMS 20061201 |
| The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. | Cancer chemotherapy and pharmacology 20060801 |
| Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. | British journal of cancer 20060619 |
| High-performance liquid chromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060501 |
| Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics. | Journal of veterinary pharmacology and therapeutics 20060401 |
| Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. | Journal of veterinary pharmacology and therapeutics 20060401 |
| Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity. | Anti-cancer drugs 20060301 |
| Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. | Nucleosides, nucleotides & nucleic acids 20060101 |
| Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry. | Molecular pharmaceutics 20060101 |
| Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. | Anti-cancer drugs 20051001 |
| Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050401 |
| Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study. | Anticancer research 20050101 |
| Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients. | Clinical pharmacokinetics 20050101 |
| Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. | Journal of controlled release : official journal of the Controlled Release Society 20041210 |
| Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector. | Acta pharmacologica Sinica 20041201 |
| Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. | Cancer 20041115 |
| Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography. | Analytical biochemistry 20040915 |
| Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040615 |
| Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. | BJU international 20040301 |
| Validated procedure for simultaneous trace level determination of the anti-cancer agent gemcitabine and its metabolite in human urine by high-performance liquid chromatography with tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20040101 |
| An expedient assay for determination of gemcitabine and its metabolite in human plasma using isocratic ion-pair reversed-phase high-performance liquid chromatography. | Therapeutic drug monitoring 20031001 |
| Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. | Cancer chemotherapy and pharmacology 20030301 |
| Measurement of the anti-cancer agent gemcitabine in human plasma by high-performance liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030225 |
| Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030215 |
| In vitro studies on the immunosuppressive effect of 2',2'-difluorodeoxycytidine (dFdC) and its metabolite 2',2'-difluorodeoxyuridine (dFdU). | Immunobiology 20030101 |
| Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20020901 |
| Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020701 |
| Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20020601 |
| Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20011101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.